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Abstract
Background—We compared the herpes simplex virus type 2 (HSV-2) seroprevalence in a 
contemporary HIV cohort with the general US population and determined risk factors for HSV-2 
infection among HIV-infected persons.
Methods—The Study to Understand the Natural History of HIV and AIDS in the Era of Effective 
Therapy (SUN) Study is a prospective observational cohort of 700 HIV-infected adults enrolled in 
4 US cities between 2004 and 2006. At baseline, participants completed a behavioral risk 
questionnaire and provided specimens for HSV-2 serology. We calculated HSV-2 seroprevalence, 
standardized by age, gender, and race among HIV-infected persons compared with the general US 
adult population, using data from the National Health and Nutrition Examination Survey from 
2003 to 2006. We examined risk factors associated with HSV-2 infection among HIV-infected 
persons using multivariate logistic regression.
Results—Among 660 (94%) SUN participants with adequate specimens for HSV-2 serologic 
testing, 548 (83%) were 20 to 49 years old (median age, 39 years; 77% male; 59% non-Hispanic 
white; median CD4 count, 470 cells/mm3; 74% with HIV RNA viral loads <400 copies/mL). 
HSV-2 seroprevalence was significantly higher among HIV-infected adults (59.7%, 95% 
confidence interval: 55.8-63.6) compared with the general US population (19.2%, 95% confidence 
interval: 17.5-21.1). In multivariate analysis, we found that older age, female gender, black non-
Hispanic race/ethnicity, being currently unemployed, high-risk anal HPV infection, and longer 
duration since HIV diagnosis were associated with significantly higher odds of HSV-2 infection.
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Conclusion—HSV-2 seroprevalence is 3 times as high among HIV-infected adults as in the 
general US population. Clinicians should be aware that increased risk for HSV-2 infection was 
distributed broadly among HIV-infected persons and not limited to those with high-risk sexual 
behaviors.
Herpes simplex virus type 2 (HSV-2) is the primary cause of genital herpes, one of the most 
common sexually transmitted infections (STI).1 As many as 95% of HSV-2 seropositive 
individuals shed HSV-2 asymptomatically, facilitating the transmission of genital herpes.2 
Recent seroprevalence studies indicate that approximately 17% of US adults aged 14 to 49 
years are chronically infected with HSV-2, showing a marked 19% decline from 1988 to 
1994.1 However, given that HSV-2 and HIV-1 share routes of transmission, the 
seroprevalence of HSV-2 among HIV-infected persons is high, ranging from 50% to 90%, 
with the highest HIV/HSV-2 coinfection rates among heterosexuals in sub-Saharan Africa 
and men who have sex with men (MSM) in the Americas.3‐6
Although it is difficult to determine the temporal order of these 2 infections, several studies 
have illustrated that infection with either HSV-2 or HIV alone markedly increases the risk of 
acquisition of the other virus.1,7 In addition, genital ulcerations caused by HSV-2 infection 
increase the risk of transmitting and acquiring HIV infection by almost 3-fold.8,9 
Furthermore, HIV-infected persons have more frequent and severe genital herpes recurrences 
and are more likely to shed HSV-2 asymptomatically than HIV-uninfected persons. 10–13 
Although lower CD4 cell counts correspond with increased frequency of HSV-2 shedding, 
even persons with CD4+ cell counts >400 cells/mm3 intermittently shed HSV-2.11–13
HIV-infected persons can benefit from HSV-2 suppressive therapy, which decreases the 
frequency and severity of HSV-2 recurrences and shedding, modestly decreases HIV viral 
load in the blood and genital secretions, and reduces the risk of HIV-1 disease 
progression.14,15 Unfortunately, many persons are unaware of HSV-2 infection because 
primary HSV-2 infection is often asymptomatic.16 Given the clinical implications regarding 
HIV transmission risk and the availability of effective HSV-2 suppressive therapies, HSV-2 
infection is an important coinfection to identify. However, there are limited data to inform 
clinicians of specific factors associated with HSV-2 serostatus among HIV-infected persons.
This analysis was designed to determine the seroprevalence of and risk factors for HSV-2 
among a contemporary cohort of HIV-infected adults compared with the general US 
population. Specifically, our objectives were to determine HSV-2 seroprevalence among 
HIV-infected and HIV-unin-fected populations for persons aged 20 to 49 years and to 
describe the demographic characteristics of each population. In addition, we determined risk 
factors associated with HSV-2 seroprevalence among a larger group of HIV-infected persons 
aged 20 to 69 years.
Methods
Study Population
The Study to Understand the Natural History of HIV and AIDS in the Era of 
Effective Therapy—The Study to Understand the Natural History of HIV and AIDS in the 
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Era of Effective Therapy (SUN) is a prospective, observational cohort study that enrolled 
700 HIV-infected adults between 2004 and 2006. Enrollees have been followed at 7 HIV 
specialty care clinics in 4 US cities: Denver, CO; Minneapolis, MN; Providence, RI; and St. 
Louis, MO. The goals of the SUN Study are as follows: (1) to monitor the incidence of 
metabolic and other medical complications related to the treatment of HIV infection and 
attendant prolonged survival; (2) to identify risk factors associated with the development of 
these metabolic and other medical complications; (3) to monitor the contribution of these 
complications and other conditions to the morbidity and mortality of HIV-infected 
individuals; and (4) to evaluate the efficacy of a structured program of prevention activities, 
which are integrated into the routine medical care of HIV patients to reduce HIV 
transmission. All enrollees have provided written informed consent to participate and to 
provide data for the study. The protocol was approved and has been annually renewed by the 
institutional review boards of the Centers for Disease Control and Prevention and of all 
participating institutions.
The SUN Study design and methods have been previously described.17 Briefly, at 
enrollment and each 6-monthly study visit, biologic specimens are collected and stored for 
future use. In addition, participants complete an audio computer-assisted self-interview that 
collects an array of clinical, social, and behavioral data, including information on substance 
use and high-risk sexual behaviors.
All participants had their HSV-2 serostatus determined at study entry (i.e., baseline) by 
Quest Diagnostics (Baltimore, MD). The assay used for detection of HSV type 2 IgG 
antibody was the FDA-approved type-specific, glycoprotein G-based (gG-2) product, 
HerpeSelect (Focus Diagnostics, Cypress, CA). This enzyme immunoassay uses a 
spectrophotometer to measure the color change associated with the presence of HSV-2 
antibodies which is quantified by an optical density. The index value is calculated by 
dividing the specimen optical density by the mean of the cutoff calibration absorbance 
values. Index values for samples that read above the absorbance limit of the 
spectrophotometer as >1.0 are positive and >5.0 are strongly positive.
National Health and Nutrition Examination Survey—National Health and Nutrition 
Examination Survey (NHANES) is a series of cross-sectional studies ongoing since 1999 
designed to assess the health and nutritional status of adults and children in the United States 
by combining interviews and physical examinations. NHANES is conducted by the National 
Center for Health Statistics, a component of the Centers for Disease Control and Prevention, 
which has the responsibility of producing health statistics for the nation. Each survey 
examines a nationally representative sample of approximately 5000 persons from 15 
counties across the United States. The NHANES interview includes demographic, 
socioeconomic, dietary, and health-related questions. The examination consists of medical, 
dental, and physiological measurements, along with laboratory tests administered by trained 
medical personnel. NHANES data and materials are collected in 2-year cycles. For this 
analysis, we used data from the NHANES 2003-2004 and 2005-2006 cycles to describe 
HSV-2 seroprevalence in the general US population.
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In both cycles, eligible persons aged 14 to 49 years were tested for HSV-2 antibodies to 
establish seropositivity using an immunodot assay. Positive samples were confirmed by a 
monoclonal antibody inhibition assay using a viral glycoprotein specific for HSV-2 (gG-2). 
In this assay, enzyme immunoassay plates are coated with a limited quantity of gG-2 
antigens. The amount of type-specific human antibodies is inversely proportional to the final 
optical density. The mean optical density obtained in the 3 negative control sera minus 3 
standard deviations determines the cutoff value for positive reaction. Human samples that 
generate optical densities less than the cutoff value are considered reactive. Further 
explanation of NHANES laboratory methodology has been previously described.18 In 
addition to HSV-2 results, we used demographic information from NHANES surveys for our 
analysis.
Statistical Analysis
Among SUN participants, we calculated the overall prevalence of HSV-2 infection adjusted 
for age, race, and gender to the US population, as well as age-adjusted (categorized by 10-
year intervals) prevalence, stratified by race (non-Hispanic white, non-Hispanic black, 
Hispanic) and gender (male, female). We estimated the same prevalence rates of HSV-2 
infection in the US adult population, aged 20 to 49 years, using sample design variables and 
sample weights to account for the complex sampling scheme used for NHANES 
2003-2006.19 To compare the prevalence of HSV-2 infection among HIV-infected persons in 
the SUN Study with that in the general population, we calculated rate ratios (RRs) for the 
entire observation period (2003-2006). Analyses were conducted using SAS version 9.1 
(SAS, Cary, NC) and SAS-callable SUDAAN (RTI International, Research Triangle Park, 
NC). Confidence intervals (CIs) were calculated using OpenEpi (Emory University, Atlanta, 
GA), when appropriate.20
Univariate analyses of associations between HSV-2 infection and potential risk factors were 
performed for all SUN Study participants, as well as MSM, men who have sex with women, 
and women, separately, using either Mantel-Haenszel χ2 or Fisher exact test for categorical 
variables and the Student t test for continuous variables. Variables included (1) demographic 
and socioeconomic status: age, gender, race, marital status, education, and employment 
status; (2) sexual risk behaviors: HIV infection risk classified as being an MSM; number of 
partners in the past 6 months; unprotected vaginal, anal, and oral sex; and STI status; (3) 
HIV-related information: time since HIV diagnosis, CD4 + cell count, HIV viral load, and 
antiretroviral treatment; and (4) substance abuse: recreational drug use, use of male 
enhancement drugs, alcohol use, and tobacco smoking history. Factors with a P value ≤0.10 
by univariate analysis were included in the multivariate logistic regression models. 
Associations were assessed using adjusted odds ratios, 95% CIs, and corresponding P 
values. Associations with P values <0.05 were considered significant. All analyses were 
conducted using SAS version 9.1 (Cary, NC).
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Prevalence of HSV-2 Infection
The Study to Understand the Natural History of HIV and AIDS in the Era of 
Effective Therapy—Among the 660 SUN participants with evaluable specimens for 
HSV-2 serology, 548 (83%) persons aged 20 to 49 years were included in the HSV-2 
prevalence estimate for comparison with NHANES. Characteristics of these SUN 
participants were as follows: median age, 39 years; 77% male; 59% non-Hispanic white; 
median CD4+ cell count, 470 cells/mm3; 95% on combination antiretroviral therapy; and 
74% with HIV RNA viral loads <400 copies/mL. Age-, race-, and gender-adjusted 
prevalence of HSV-2 infection was 59.7% (95% CI: 55.8– 63.6). HSV-2 prevalence was 
significantly higher among women (81.3%, 95% CI: 73.8–87.3) than men (53.6%, 95% CI: 
48.8–58.3) and significantly higher among non-Hispanic blacks (77.1%, 95% CI: 70.0–83.1) 
than non-Hispanic whites (52.3%, 95% CI: 46.9–57.7). HSV-2 prevalence was similar 
among MSM (54.1%, 95% CI: 48.6-59.5) and men who have sex with women (51.3%, 95% 
CI: 39.7-62.8).
National Health and Nutrition Examination Survey—Persons aged 20 to 49 years 
surveyed for the 2003-2006 NHANES cycles who met the HSV-2 testing criteria represented 
approximately 115 million US adults (median age, 34 years; 49% male; 67% non-Hispanic 
white; 0.53% HIV-infected). Overall HSV-2 prevalence was 19.2% (95% CI: 17.5– 21.1). 
HSV-2 prevalence was significantly higher among women (24.8%, 95% CI: 22.5-27.2) than 
men (13.5%, 95% CI: 11.6-15.6) and significantly higher among non-Hispanic blacks 
(47.5%, 95% CI: 43.8-51.1) than non-Hispanic whites (14.7%, 95% CI: 13.0-16.6).
SUN and NHANES Comparisons—The prevalence of HSV-2 infection was >3 times as 
high among HIV-infected persons as among adults in the general US population (RR = 3.1, 
95% CI: 2.7-3.7); a similar trend was observed among men (RR = 3.5, 95% CI: 2.7-4.4) and 
women (RR = 3.3, 95% CI: 2.7-3.8) when examined separately. Among HIV-infected non-
Hispanic white men, Hispanic men, and non-Hispanic black men compared with the same 
groups in the general US population, the RRs were 4.0 (95% CI: 2.8-5.5), 5.4 (95% CI: 
2.9-9.9), and 1.6 (95% CI: 1.2-2.1), respectively (Fig. 1A). Among the HIV-infected women, 
the RRs for non-Hispanic white women, Hispanic women, and non-Hispanic black women 
were 4.0 (95% CI: 2.9-5.1), 2.7 (95% CI: 1.6-4.5), and 1.6 (95% CI: 1.3-1.8), respectively, 
compared with the same groups in the general US population (Fig. 1B).
Factors Associated With HSV-2 Infection Among HIV-Infected Persons
Among the 660 SUN participants, the median age was 41 years, 78% were male, 60% were 
non-Hispanic white, the median CD4 cell count was 469 cells/mm3, and 74% had an HIV 
RNA viral load <400 copies/mL (Table 1). By multivariate analyses, factors independently 
associated with HSV-2 infection included older age, female gender, non-Hispanic black 
race/ethnicity, current unemployment, infection with high-risk anal HPV, and duration since 
HIV diagnosis >2.3 years (lowest quartile) (Table 2). In the multivariate analysis limited to 
women (n = 148), factors independently associated with HSV-2 infection included older age, 
non-Hispanic black race/ethnicity, and current unemployment (Table 3). In the multivariate 
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analysis limited to MSM (n = 415), factors independently associated with HSV-2 infection 
included older age, non-Hispanic black race/ethnicity, and history of injection drug use 
(Table 4).
Discussion
This is the first study to compare HSV-2 seroprevalence among a contemporary cohort of 
HIV-infected adults in the United States with adults in the general US population; these 
results highlight the striking differences in HSV-2 seroprevalence, which is 3 times as high 
among HIV-infected adults. Nevertheless, the trends in HSV-2 seroprevalence in both 
populations were similar and consistent with those already reported in the literature.1,4,21
HSV-2 is a lifelong incurable infection; therefore, an increase in HSV-2 seroprevalence with 
increasing age is anticipated and is consistent with previous reports.1,4,21 The women in our 
HIV cohort had a particularly high risk of HSV-2 infection compared with men. Women are 
at greater risk of HSV-2 infection1,4,21 because of higher efficiency of HSV-2 transmission 
from men to women as compared with that from women to men,22,23 and anatomical 
differences of the female genital tract, including the lack of an intact stratum corneum and 
large surface area, which is susceptible to abrasions.24 With regard to race, our results were 
similar to other studies that found that nonwhites have an increased risk of HSV-2 
infection.1,4,21 This disparity may be due to several factors, such as variation in HSV-2 assay 
performance among certain populations,25 higher prevalence of poverty, lower 
socioeconomic status, limited access to health care, differences in sex behaviors and health-
related behaviors, and illicit drug use.26
By multivariate analysis, independent factors associated with HSV-2 infection were older 
age, female gender, non-Hispanic black race, being unemployed, infection with a high-risk 
anal HPV type, and longer duration since HIV diagnosis. Because HPV, HSV-2, and HIV 
infections are all chronic viral STIs, which share transmission routes and risk behaviors,27 
the association of high-risk HPV infection with HSV-2 infection among HIV-infected 
persons is biologically plausible, and underscores the need to screen for multiple viral STIs 
when a patient presents with any one of them. Furthermore, the association of longer 
duration of HIV infection with HSV-2 infection is not surprising because HIV-infected 
people live longer, and are able to maintain sexually active lives while on highly active 
antiretroviral therapy. Anogential herpes was one of the first opportunistic infections 
described among persons with AIDS, and persistent herpetic ulceration is an AIDS-defining 
illness, demonstrating that coinfection with these 2 sexually transmitted viruses has been 
recognized since the beginning of the epidemic.28
Surveillance data from 2006 indicate that nearly half (48.1%) of all HIV-infected persons in 
the United States are MSM.29 Although MSM are a principal risk group for HIV infection in 
the United States, we found no significant association between HSV-2 infection and being 
an MSM as opposed to other risk groups, consistent with a recent Canadian study.4 In our 
multivariate analysis limited to MSM, we found that older age, non-Hispanic black race, and 
any history of injection drug use were independently associated with HSV-2 infection. 
Because HSV-2 is primarily transmitted through sexual activities, the association with 
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injection drug use is an unexpected, but not novel, finding. At least 1 other study has 
reported this finding, specifically with cocaine use.1 MSM who inject drugs likely engage in 
multiple risk behaviors for HIV infection because these illicit substances potentially enhance 
sexual pleasure. Also, intoxication and consequent disinhibition leads to risky behavior, for 
example, unprotected sex or sex with multiple partners.30 Furthermore, injection drug users 
may be more likely to change their drug injection behavior (e.g., seek treatment or use clean 
syringes) than practice sexual risk reduction to avoid spreading HIV, which may explain this 
association.31
Our study is subject to limitations. Compared with the US population of HIV-infected 
adults, the population from which SUN Study participants were recruited was older, with a 
greater proportion of whites and of persons exposed to HIV through homosexual or bisexual 
activity.32 Participants in the SUN Study receive continuous care and have well-controlled 
HIV infection through highly active antiretroviral therapy; consequently, these individuals 
generally maintain good health. In addition, the SUN Study did not enroll persons with a 
current opportunistic infection or persons who are not in care. As a result, the SUN Study 
data may not be generalizable to the entire HIV-infected population of the United States. 
Finally, we did not exclude HIV-infected persons from the general US population data 
(NHANES). However, the percentage of HIV-infected people in the NHANES cohort was 
<1%. Because this number is small, the overall analysis is not likely to have been 
significantly affected by their inclusion.
In conclusion, HSV-2 seroprevalence was 3 times as high among HIV-infected adults 
compared with the general US population. However, risk factors for HSV-2 infection—older 
age, female gender, and non-Hispanic black race—were similar among HIV-infected persons 
and the general US population. HSV-2 seroprevalence remains high among HIV-infected 
individuals because the same behaviors confer risk for both HSV-2 and HIV infection. 
Interestingly, as a principal risk group for HIV infection, MSM from our HIV-infected 
cohort were not disproportionately likely to be HSV-2 coinfected. Nor were high-risk sexual 
behaviors among our HIV-infected cohort significantly associated with HSV-2 infection. The 
failure to observe these associations is a reflection of the extremely high HIV-HSV-2 
coinfection rates among all participants in the study. Clinicians should be aware that the risk 
for HSV-2 infection is broadly distributed among HIV-infected adults, including MSM, and 
does not necessarily concentrate among persons who report high-risk sexual behaviors. 
Emerging data suggest that HSV suppression can reduce risk of HIV-1 disease progression, 
which not only benefits coinfected individuals but also may reduce HIV transmission in the 
community. Acyclovir is an effective, inexpensive, and widely available drug. A recent 
meta-analysis showed that HSV treatment may result in a clinically meaningful decrease in 
HIV viral load, which is more pronounced among persons on antiretroviral therapy who as a 
result have a lower risk of AIDS progression and death.33 Therefore, routine screening of 
HIV-infected patients for HSV-2 infection in HIV clinics requires serious consideration.
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A, HSV-2 seroprevalence among men, by age and race, SUN versus NHANES, 2003–2006. 
B, HSV-2 seroprevalence among women, by age and race, SUN versus NHANES, 2003–
2006.
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Table 1
Characteristics of SUN Study Participants, 2004–2006
Characteristic All Participants N = 
660n (%)
Men Who HaveSex 
With Menn = 415n 
(%)
Women n = 148n 
(%)
Men Who HaveSex 
With Womenn = 97n 
(%)
HSV-2 infected 408 (62) 235 (57) 122 (82) 51 (53)
Median age (IQR) 41 (35–47) 42 (36–47) 39 (32–45) 42 (37–48)
Male gender 512 (78) 415 (100) 0 (0) 97 (100)
Currently married/living with partner (n 
= 588)
390 (66) 236 (66) 109 (75) 45 (52)
Race/ethnicity
 White, non-Hispanic 393 (60) 316 (76) 44 (30) 33 (34)
 Black, non-Hispanic 190 (29) 60 (14) 84 (57) 46 (47)
 Hispanic 62 (9) 34 (8) 14 (9) 14 (14)
 Other 15 (2) 5 (1) 6 (4) 4 (4)
High school graduate (n = 616) 539 (87) 362 (94) 108 (75) 69 (81)
Employed full time (n = 654) 310 (47) 238 (58) 38 (26) 34 (35)
Sexual activity in last 6 mo
 None 177 (27) 78 (19) 57 (39) 42 (43)
 1 partner 253 (38) 133 (32) 75 (51) 45 (46)
 2–3 partners 109 (17) 90 (22) 11 (7) 8 (8)
 4 or more partners 120 (18) 113 (27) 5 (3) 2 (2)
 Unprotected vaginal or anal sex 208 (32) 162 (39) 34 (23) 12 (12)
CD4 cell count (cells/mm3)
 Median baseline (IQR) 469 (333–678) 482 (345–692) 458 (335–691) 442 (288–572)
 Median nadir (IQR) 205 (90–320) 213 (100–339) 212 (102–312) 138 (56–284)
HIV History
 Median years since HIV diagnosis
 AIDS diagnosis 154 (23) 90 (22) 33 (22) 31 (32)
 Median viral load (log10, IQR) (n = 
656)
Und (Und–2.70) Und (Und–Und) Und (Und–3.19) Und (Und–Und)
 HIV viral load >400 copies/mL 486 (74) 314 (76) 99 (67) 73 (76)
 Current combination antiretroviral 
therapy
520 (79) 330 (80) 109 (74) 81 (84)
Ever drug use
 Marijuana 480 (73) 328 (79) 93 (63) 59 (61)
 Cocaine 323 (49) 211 (51) 69 (47) 43 (44)
 Injection drug use 90 (14) 44 (11) 23 (16) 23 (24)
 Inhaled nitrites 318 (48) 300 (72) 6 (4) 12 (12)
 Erectile dysfunction drugs* 177 (35) 157 (38) N/A 20 (21)
Current drug use (in last 6 mo)
 Marijuana 212 (32) 148 (36) 36 (24) 28 (29)
 Cocaine 85 (13) 42 (10) 27 (18) 16 (16)
 Injection drug use 14 (2) 7 (2) 5 (3) 2 (2)
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Characteristic All Participants N = 
660n (%)
Men Who HaveSex 
With Menn = 415n 
(%)
Women n = 148n 
(%)
Men Who HaveSex 
With Womenn = 97n 
(%)
 Inhaled nitrites 126 (19) 123 (30) 2 (1) 1 (1)
 Erectile dysfunction drugs* 84 (16) 73 (18) N/A 11 (11)
Current smoking 291 (44) 172 (41) 75 (51) 44 (45)
Alcohol consumption in past 30 d 457 (69) 324 (78) 77 (52) 56 (58)
Cervical HPV (n = 142)
 Any HPV 123 (87) N/A 123 (87) N/A
 High-risk HPV 96 (68) N/A 96 (68) N/A
 Low-risk HPV 81 (57) N/A 81 (57) N/A
Anal HPV (n = 643)
 Any HPV 571 (89) 382 (95) 132 (90) 57 (59)
 High-risk HPV 527 (82) 354 (88) 122 (84) 51 (53)
 Low-risk HPV 486 (76) 339 (85) 108 (74) 39 (41)
*
Men only.
HSV indicates herpes simplex virus; IQR, interquartile range; Und, undetermined; HIV, human immunodeficiency virus; AIDS, acquired 
immunodeficiency syndrome; HPV, human papillomavirus.
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Table 2
Logistic Regression Analysis of Factors Associated With HSV-2 Prevalence Among SUN 
Study Participants
Characteristic Univariate Analysis (N = 660) 
OR (95% CI)
P Multivariate Analysis (n = 




 30–39 1.74 (1.01, 3.02) 0.048 2.54 (1.35, 4.88) 0.004
 40–49 2.27 (1.33, 3.90) 0.003 2.95 (1.57, 5.63) <0.001
 50 + 2.93 (1.58, 5.53) <0.001 3.87 (1.89, 8.12) <0.001
Gender, female 3.71 (2.38, 5.97) <0.001 3.04 (1.82, 5.25) <0.001
Black, non-Hispanic 3.08 (2.10, 4.61) <0.001 2.53 (1.61, 4.05) <0.001
Current unemployment 2.83 (2.09, 4.16) <0.001 1.98 (1.36, 2.91) <0.001
High-risk anal HPV infection 1.41 (0.93, 2.11) 0.100 1.69 (1.07, 2.67) 0.025
Duration since HIV diagnosis >2.3 yr (lower 
quartile)
2.08 (1.45, 2.99) <0.001 1.54 (1.03, 2.30) 0.033
Current cocaine use (in previous 6 mo) 2.06 (1.24, 3.54) 0.006 NS
History of opportunistic infection 1.67 (1.14, 2.49) 0.009 NS
Current marijuana use (in previous6mo) 1.35 (0.96, 1.90) 0.088 NS
OR indicates odds ratio; NS, nonsignificant.
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Table 3
Logistic Regression Analysis of Factors Associated With HSV-2 Prevalence Among 
Women in the SUN Study
Characteristic Univariate Analysis (n = 148) OR 
(95% CI)
P Multivariate Analysis (n = 147) adjOR 
(95% CI)
P
Age >32 yr (lower quartile) 3.16 (1.30, 7.70) 0.011 3.58 (1.37, 9.58) 0.010
Black, non-Hispanic 2.47 (1.05, 6.06) 0.042 3.00 (1.19, 8.10) 0.023
Current unemployment 4.13 (1.72, 10.5) 0.002 4.42 (1.76, 11.9) 0.002
Cervical HPV infection 4.86 (1.66, 14.0) 0.003 NS
High-risk anal HPV infection 3.09 (1.11, 8.23) 0.026 NS
Health very good/excellent 0.39 (0.16, 0.92) 0.032 NS
History of opportunistic infection 4.09 (1.12, 26.3) 0.066 NS
Current cocaine use in previous 6 mo 6.77 (1.33, 123) 0.067 NS
Current smoking 2.23 (0.94, 5.59) 0.076 NS
OR indicates odds ratio; adjOR, adjusted odds ratio; HPV, human papillomavirus; NS, nonsignificant.
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Table 4
Logistic Regression Analysis of Factors Associated With HSV-2 Prevalence Among MSM 
in the SUN Study
Characteristic Univariate Analysis (n = 415) 
OR (95% CI)
P Multivariate Analysis (n = 
415) adjOR (95% CI)
P
Age (yr)
 20–29 Ref Ref
 30–39 2.78 (1.24, 6.72) 0.017 3.62 (1.54, 9.22) 0.004
 40–49 4.57 (2.08, 10.9) <0.001 5.76 (2.51, 14.4) <0.001
 50 + 6.04 (2.51, 15.6) <0.001 7.96 (3.17, 21.6) <0.001
Black, non-Hispanic 2.15 (1.20, 4.00) 0.012 2.90 (1.54, 5.77) 0.001
Current unemployment 2.18 (1.40, 3.43) <0.001 NS
Duration since HIV diagnosis >2.3 yr (lower quartile) 2.04 (1.30, 3.22) 0.002 NS
History of opportunistic infection 1.71 (1.06, 2.82) 0.031 NS
Nadir CD4 <50 cells/mm3 1.85 (1.06, 3.32) 0.035 NS
History of injection drug use 2.88 (1.43, 6.30) 0.005 3.57 (1.72, 8.06) 0.001
History of inhaled nitrites use 1.48 (0.96, 2.29) 0.073 NS
Current marijuana use (in previous 6 mo) 1.42 (0.95, 2.15) 0.091 NS
OR indicates odds ratio; adjOR, adjusted odds ratio; NS, nonsignificant.
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